Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease

Xadago (ZAH-dah-goh) will be a new add-on for Parkinson's disease.

Think of Xadago (safinamide) as similar to selegiline (Eldepryl, etc) or rasagiline (Azilect, etc).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote